Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing...
Alfasigma S.p.A. tender offer for Intercept Pharmaceuticals, Inc. commences
ALFASIGMA ACQUIRES THE ENTIRE SHARE CAPITAL OF SOFAR, AN ITALIAN PHARMACEUTICAL COMPANY
Alfasigma Group Redeploys CARNITENE® (L-carnitine) Business in the Chinese Market
Alfasigma launches diagnostic drug Lumeblue™ ahead of World Digestive Health on 29 May
Alfasigma inaugurates the new Research and Development center in Pomezia named after its founder Marino Golinelli
Alfasigma: Jacopo Murzi is the new General Manager of the Italy Business Unit
Alfasigma acquires Lumeblue™ (Methylene Blue MMX) rights for EU distribution, consolidating its Gastro-Intestinal portfolio